FREE MARKET CAPITALIST RAMBLINGS FROM THE END OF THE BAR
Monday, November 1, 2021
T-Cell Immunotherapy stock $PDSB primed to run?
In evaluating PDS Biotechnology, noting immunotherapy is considered as perhaps having the greatest area of potential for developing effective cancer drugs utilizing our own immune system, I found the company description really attractive.
Is T-Cell immunotherapy stock $PDSB primed to run?
BAHL is a REALTOR, Real Estate Investor and Residential Real Estate Appraiser in Orlando. He holds a BS degree in Economics from Florida State University.
No comments:
Post a Comment